CalciMedica, Inc. - 8-K Filing
CalciMedica reported Q1 2026 financial results with $8.2 million in cash as of March 31, net income of $5.0 million ($0.31 per basic share), driven by a $9.1 million increase in other income from fair value adjustments to its promissory note and warrants. R&D expenses were $3.5 million for the quarter compared to $4.2 million in Q1 2025, while G&A expenses decreased slightly to $2.1 million. (Items: 2.02 Results of Operations and Financial Condition, 9.01 Financial Statements and Exhibits)
Tickers: $CALC